ΔΎΉΟΦ±²₯

Meeting Coverage

ASCO

American Society of Clinical Oncology

Metformin Fails to Stop Early Prostate Cancer Progression

Study suggests it may even be detrimental in some groups of patients on active surveillance

ASCO over a photo of McCormick Place in Chicago, IL

Latest ASCO Meeting Coverage

Docetaxel Tied to Less Taxane Neuropathy in Black Breast Cancer Patients

Dose-limiting toxicity has been linked with worse outcomes specifically in this population

June 5, 2024
Neoadjuvant Strategy Establishes Standard of Care for Resectable Stage III Melanoma

A third as many clinical events versus adjuvant therapy, 6 weeks of treatment for many patients

June 4, 2024
ctDNA Analysis Not Enough to Guide Chemo De-Escalation in Early Pancreatic Cancer

Adjuvant chemo de-escalation based on ctDNA had no effect on recurrence-free survival

June 4, 2024
A Win for Liver Transplantation in Unresectable Metastatic Colorectal Cancer

Three new trials address CRC liver metastases

June 4, 2024
New Drug Effective for Tenosynovial Giant Cell Tumors, and With No Liver Concerns

Current option for rare tumor requires a REMS to monitor for drug-induced liver injury

June 4, 2024
Dual Immunotherapy Improves Response Rates in Gynecologic Clear Cell Cancers

Clear cell histology "is what yields the super response we see in these trials," expert suggests

June 4, 2024
Cheap Drug Eases Hot Flashes in Men With Prostate Cancer

Anticholinergic oxybutynin for patients taking ADT also improved quality of life in the process

June 3, 2024
Limited-Stage SCLC Gets a New Standard of Care With Consolidation Durvalumab

Median OS was 55.9 months in the durvalumab group compared with 33.4 months in the placebo group

June 3, 2024
Perioperative Chemo Extends Survival in Resectable Esophageal Cancer

Improvement also observed in complete remission rates with FLOT over CROSS regimen

June 3, 2024
Lymphadenectomy Not Needed in Advanced Ovarian Cancer With Optimal Surgery

PFS was not significantly different for those who skipped lymphadenectomy

June 3, 2024
Triplet Notches Survival Win in Heavily Pretreated DLBCL

Benefit with BV plus lenalidomide-rituximab seen in those who relapsed after CAR-T or transplant

June 2, 2024
Antibody-Drug Conjugate Picks Up Another Win in HR+/HER2-low Breast Cancer

Trastuzumab deruxtecan extended its superiority versus chemotherapy into HER2-ultralow

June 2, 2024
Novel CD40 Agonist-Chemo Combo Shows Promise in Pancreatic Cancer

Frontline treatment with mitazalimab plus mFOLFIRINOX achieved responses in 40% of patients

June 2, 2024

Videos